The largest database of trusted experimental protocols

2 protocols using wm 239

1

MALDI-TOF Mass Spectrometry of Melanoma Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Trifluoroacetic acid (TFA) (99.0%) was obtained from Acros Organics (New Jersey, USA). Cytochrome C (CytC), trypsin, 2,5dihydroxybenzoic acid (DHB), α-cyano-4-hydroxycinnamic acid (HCCA) and sinapic acid (SA) were purchased from Sigma-Aldrich (St Gallen, Switzerland). Methanol, acetone, ethanol and acetonitrile were obtained from Merck (Dietikon, Switzerland) and formaldehyde solution (4% in PBS) was from Alfa-Aesar (Karlsruhe, Germany). Deionized water was produced by the Alpha Q Millipore system (Zug, Switzerland).
The matrices containing 10 mg per mL of SA, 10 mg per mL of DHB or 10 mg per mL of HCCA were prepared in the solution containing 70% of acetonitrile, 29.9% of water and 0.1% of TFA in terms of v/v. WM-239, WM-115 and Sbcl2 human melanoma cell lines were purchased from the American Type Culture Collection (ATCC).
+ Open protocol
+ Expand
2

Melanoma Cell Lines and Vemurafenib Resistance

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human melanoma cell lines (A375, SK-mel-28, UACC903, MGH-MC-1, K4, WM239, WM1158, WM164, G-mel, CHL-1, SK-mel-119) were developed in-house, purchased from the American Type Culture Collection (Rockville, MD) or gifts from Meenhard Herlyn (Wistar Institute, Philadelphia, PA). Vemurafenib resistant melanoma cell lines (A375-P, SK-Mel 28-P, UACC903-P, MGH-MC-1-P, K4-P, WM239-P and WM1158-P) were obtained by sequentially exposing of cells to escalating doses of VEM in 2014. DMEM medium with 10% fetal bovine serum (FBS), supplemented with 100 units/ml penicillin, 100 μg/ml streptomycin, and 2 mM glutamine was used for routine culturing of cells; VEM-resistant cells were cultured in VEM-free media for 10–14 days prior to re-testing VEM sensitivity; this drug holiday period had no effect on the VEM resistance (data not shown). All cells were incubated in a humidified atmosphere of 95% air and 5% CO2 at 37°C. Tumor specimens from patients were obtained prior to treatment with BRAFi (vemurafenib) or BRAFi+MEKi (dabrafenib+trametinib) and post-relapse as indicated in Table S1. Acquisition of tissue was covered under a protocol approved by the DF/Harvard Cancer Center (legacy #11-181; Boston, U.S.) in accordance with the Declaration of Helsinki.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!